Eli Lilly's Once-Weekly Insulin Onswik Approved by U.S. FDA
nashnova research
Eli Lilly's once-weekly basal insulin Onswik won FDA approval for type 2 diabetes, cutting annual injections by over 300 — a landmark shift from daily to weekly insulin dosing.
What problem does this drug actually solve?
Onswik is a basal insulin — the "baseline" insulin that keeps blood sugar steady around the clock — dosed once a week.
Current standard basal insulins, insulin glargine U-100 and insulin degludec U-100, require daily injections.
This means → patients go from 365-plus shots a year to roughly 52, eliminating over 300 needles annually.
Does fewer injections mean weaker results?
Approval rests on Lilly's QWINT Phase 3 trials; Onswik hit its primary endpoint with glucose control on par with daily insulins.
In plain terms = injection frequency drops by about 85%, with no loss in blood-sugar management.
Lilly plans to launch in two concentrations — 500 units/mL and 1,000 units/mL — to cover different dosing needs.
Where does global rollout stand?
The U.S. is Onswik's fourth regulatory approval, following Europe, Mexico, and Japan.
This means → Lilly now holds clearance across every major regulatory region, laying the groundwork for a broad commercial launch.
The key question ahead: whether multi-market approvals translate into real insulin market-share gains will hinge on pricing strategy and payer-negotiation progress.
市场有风险，内容仅供研究参考，不构成投资建议。